Document:

<PAGE>
                                                                   EXHIBIT 10.18

                          *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
                                  DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
                                    AND FILED SEPARATELY WITH THE SECURITIES AND
                                 EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
                                             SECURITIES ACT OF 1933, AS AMENDED.

                                LICENSE AGREEMENT

         This License Agreement ("AGREEMENT") is made as of this 8th day of
October, 2001 (the "EFFECTIVE DATE") by and between ABBOTT DEUTSCHLAND HOLDING
GmbH, a German legal entity, with its principal office at Max Planck Ring 2,
65205 Wiesbaden, Germany ("ABBOTT") and MYOGEN, INC., a Delaware corporation,
with its principal office at 7577 W. 103rd Avenue, Westminster, CO 80021-5426
("MYOGEN").

                                   WITNESSETH

         WHEREAS, Abbott is the holder or licensee of certain patent
applications and patents ("Patents," as more fully defined below) relating to
Compound (as defined below);

         WHEREAS, Abbott also possesses proprietary Know-How (as defined below)
relating to Compound; and

         WHEREAS, Myogen wishes to obtain, and Abbott wishes to grant to Myogen,
an exclusive license in the Territory (as defined below) under Abbott's
Technology (as defined below) for the development and commercialization of
Product for Pharmaceutical Uses (as defined below).

         NOW THEREFORE, in consideration of the mutual obligations and promises
as set forth herein, the parties do hereby agree as follows:

1. DEFINITIONS. As used in this Agreement, the following terms shall have the
following respective meanings:

         1.1 "ABBOTT'S TECHNOLOGY" means the Patents and Know-How, including all
Improvements developed by Abbott and Improvements that are jointly developed by
Abbott and Myogen pursuant to Article 13.

         1.2 "AFFILIATE" means any corporation, company, partnership, joint
venture and/or firm which controls, is controlled by, or is under common control
with either party hereto. For purposes of this definition, control shall mean
direct or indirect ownership of more than fifty percent (50%) of the stock or
participating shares entitled to vote for the election of directors (but only as
long as such ownership exists).

         1.3 "CHF" means the indication commonly known as chronic heart failure.

         1.4 "COMBINATION PRODUCT" means a pharmaceutical product that is
comprised in part of Product and in part of one or more other active agents in
any configuration, formulation or combination.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

         1.5 "COMPOUND" means the endothelin receptor antagonist compound
identified as BSF 208075 (ambrisentan) with the following formula:

[GRAPHIC FORMULA]

and the chemical name,(+)-(S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3-
diphenyl propionic acid, its racemates, isomers, Prodrugs, active metabolites
and any pharmaceutically acceptable salt or complex thereof, in its current and
any other formulation, whether made before or after the Effective Date.

         1.6 "CONFIDENTIAL INFORMATION" means any and all information or data
relating to the Compound and/or Product which a party discloses to the other
party, its employees or representatives, or is conceived or reduced to practice
during the Term by either party or by a third party conducting feasibility and
evaluation studies for Myogen, whether in writing, orally or by observation,
including, without limitation, all scientific, clinical, technical, commercial,
financial and business information and Know-How, and other information or data
considered confidential in nature. Confidential Information shall not include
information or any portion thereof which:

                  (a) is known to the receiving party at the time of disclosure
and documented by written records made prior to the date of this Agreement;

                  (b) is subsequently disclosed to the receiving party without
any obligations of confidence by an unaffiliated third person who has not
obtained it directly or indirectly from the other party and who has the right to
make such disclosure;

                  (c) becomes patented, published or otherwise part of the
public domain; or

                  (d) is independently developed by or for the receiving party
by person(s) having no knowledge of or access to such information and without
breach of any confidentiality obligation as evidenced by its written records.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

The contents of and the Exhibits to this Agreement shall constitute Confidential
Information.

         1.7 "CRF" means the indication commonly known as chronic renal failure.

         1.8 "EFFECTIVE DATE" shall have the meaning ascribed to such term in
the opening paragraph of this Agreement.

         1.9 "FIRST COMMERCIAL SALE" means the first sale of Product in the
Territory, after Regulatory Approval, by Myogen, any Affiliates or sublicensees
of Myogen, or any contract sales force of Myogen or its Affiliates, to any
unaffiliated third party as evidenced by the selling party's invoice or other
relevant document provided to such third party. A sale to an unaffiliated third
party shall not include quantities delivered solely for research purposes, for
clinical trials or quantities distributed as free samples or promotions.

         1.10 "IMPROVEMENTS" means all additions, developments, modifications,
enhancements and adaptations (i) which directly relate to or are used in
connection with the Compound and/or Product, or any formulations thereof or
additions, developments, modifications, enhancements, improvements and
adaptations thereto, and (ii) which are conceived or reduced to practice during
the Term. Ownership of Improvements shall be as set forth in Article 13 hereof.

         1.11 "IND" means an investigational new drug application filed with the
applicable Regulatory Authority in a country of the Territory, in order to
commence human clinical testing of a drug. An IND, together with all
supplemental filings referencing the initial IND filing, shall be deemed one and
the same IND for all purposes of this Agreement.

         1.12 "KNOW-HOW" means any proprietary technology, information, methods
of use, processes, techniques, ideas or inventions (other than the Patents)
owned, possessed or used by Abbott as of the Effective Date which is directly
related to or used in connection with the Compound and/or Product, including all
trade secrets and any other technical information relating to development, use
or sale of the Compound and/or Product, provided that Abbott has the right to
license and/or sublicense to Myogen.

         1.13 "MANUFACTURING DEVELOPMENT AND SUPPLY AGREEMENT" means an
agreement between the parties for the manufacture and supply of Compound and/or
Product as contemplated and described more fully under Section 4.6(a) below.

         1.14 "NDA" means an application (whether original, supplementary or
abbreviated) to the applicable Regulatory Authority in a country of the
Territory, for approval by such Regulatory Authority, necessary for the
commercial sale of Product in

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

such country. An NDA, together with all supplemental filings referencing the
initial NDA filing, shall be deemed one and the same NDA for all purposes of
this Agreement.

         1.15 "NET SALES" means gross sales of the Product to unrelated third
parties, in arm's length transactions, for which revenue is actually received by
Myogen, by any Affiliates or sublicensees of Myogen, or any contract sales force
of Myogen or its Affiliates, including, but not limited to, pharmaceutical
wholesalers, pharmacies, hospitals or dispensing physicians, less any of the
following charges or expenses that are incurred in connection with gross sales
of the Product during the Term:

                  (a) discounts, including cash discounts, customary trade
allowances or rebates actually taken, governmental rebates, chargebacks,
commissions, and group purchasing management fees for formulary access;

                  (b) credits or allowances given or made for rejection, recall
or return of previously sold Product actually taken;

                  (c) any tax or government charge, duty or assessment
(including any tax such as a value added or similar tax or government charge)
levied on the sale, transportation or delivery of Product when included on the
invoice or other written document between the parties as payable by the
purchaser and collectable by Myogen, its Affiliate or sub-licensee; and

                  (d) freight, postage, transportation, insurance and duties on
shipment of Product when included on the invoice or other written document
between the parties as payable by the purchaser and collectable by Myogen, its
Affiliates or sublicensees.

                  With respect to a Combination Product, Net Sales of such
Combination Product shall first be calculated in accordance with Net Sales of
Product above, and then the Net Sales of such Combination Product shall be
determined on a country-by-country basis as follows:

                           [...***...]

         1.16 "PATENTS" means the patent applications and patents listed in
Exhibit A hereto and any and all other patent applications and patents and
amendments thereto, including foreign equivalents, and any and all
substitutions, extensions, additions, reissues, re-examinations, renewals,
divisions, continuations, continuations-in-part or supplementary protection
certificates owned by or licensed to (with the right to sublicense) Abbott or
its Affiliates during the Term relating to the Compound, Product or any
Improvements.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

         1.17 "PAH" means the indication commonly known as pulmonary arterial
hypertension.

         1.18 "PHARMACEUTICAL USES" means any therapeutic use in humans of the
Compound and/or Product in any formulation or dosage form for the management or
treatment or prevention of a disease or condition of the human body, including,
but not limited to, chronic heart failure (CHF), chronic renal failure (CRF) and
pulmonary arterial hypertension (PAH), but excluding [...***...].

         1.19 "PRODRUG" means different pharmaceutical compounds which,
following administration, are converted into structurally similar active
metabolites.

         1.20 "PRODUCT" means any formulation containing the Compound or any
Improvement as an active ingredient for Pharmaceutical Uses.

         1.21 "REGULATORY APPROVAL" means all governmental approvals and
authorizations necessary for the commercial sale of the Product in a country of
the Territory, including, but not limited to, marketing authorization, pricing
approval and pricing reimbursement, as applicable.

         1.22 "REGULATORY AUTHORITY" means the United States Food and Drug
Administration or any successor entity and its equivalent in other countries of
the Territory, including, but not limited to, EMEA.

         1.23 "ROYALTY PERIOD" shall have the meaning ascribed to such term in
Section 5.4(a) of this Agreement.

         1.24 "TERM" means the period commencing on the Effective Date and
terminating as set forth in Article 8 below.

         1.25 "TERRITORY" means the entire world.

         1.26 "TRADEMARK" means any trademark registered, owned or chosen for
Product by Myogen in any country of the Territory.

         1.27 "VALID CLAIM" means a claim of an unexpired Patent that has not
been withdrawn, canceled or disclaimed nor held to be invalid or unenforceable
by a court or government agency of competent jurisdiction in an unappealed or
unappealable decision.

         1.28 "WORK PLAN" means the summary of the current development plan for
BSF 208075, which summary is attached hereto as Exhibit B.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

2. LICENSE GRANT.

         2.1 Abbott hereby grants to Myogen an exclusive right and license in
the Territory, under Abbott's Technology, for all Pharmaceutical Uses, with the
right to grant sublicenses pursuant to Section 4.7 hereof, to (i) research,
develop, modify and improve Compound and Product; (ii) apply for and obtain
Regulatory Approvals; and (iii) use, import/export, market, offer to sell and
sell, Product and Compound.

         2.2 In the event Myogen exercises its rights under Section 4.6(a) or
Section 4.6(c) hereof to self-manufacture Compound and/or Product, then the
exclusive license granted under Section 2.1 above shall be deemed to include the
rights to make Compound and Product.

         2.3 In the event Myogen exercises its rights under Section 4.6(b) or
Section 4.6(c) hereof to qualify a second source (including itself) to
manufacture Product or to engage a third party manufacturer for finishing
Compound and/or Product, then the exclusive license granted under Section 2.1
above shall be deemed to include the rights to make or have made Compound and
Product, as the case may be.

3. INFORMATION; EXCLUSIVITY.

         3.1 CONVEYANCE OF INFORMATION/INVENTORY.

             (a) Within thirty (30) days following the Effective Date, Abbott
and Myogen shall work together to (i) identify information and documents under
Abbott's and its Affiliates' control involving the Compound that will be useful
to Myogen in the transfer of development activities hereunder and (ii) establish
a timeline for delivery of such information and documents. Abbott shall convey
such information to Myogen in accordance with such timeline, but in no event
later than ninety (90) days following its identification by the parties. For
purposes of this Section 3.1, information shall not be deemed under Abbott's and
its Affiliates' control if such information is protected by confidentiality
agreements with third parties; provided, however, that Abbott shall provide
Myogen with notice that such information is subject to third party
confidentiality obligations at the time of its identification. With respect to
such protected information, Abbott shall use reasonable efforts to obtain the
consent of such third parties to release the protected information to Myogen.

             (b) [***], Abbott shall convey the quantities of Product and
matched placebo specified on Exhibit E which are currently in inventory. Abbott
shall supply Myogen with [...***...]. Abbott expects that it will be able to
communicate such [...***...] cost to Myogen within ninety (90) days of the
Effective Date. Abbott shall utilize [...***...] of Compound currently in
inventory to manufacture such Product and [...***...] Myogen for the cost of
[...***...] of Compound. In the event any excess Compound remains after the
manufacture of the

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

Product as provided herein, such excess shall be conveyed to Myogen [...***...].
If additional Compound greater than [...***...] is needed to manufacture the
Product quantities specified on Exhibit E or if Myogen requests additional
Compound, Myogen shall pay Abbott or its designated Affiliate [...***...].

                  (c) Abbott represents and warrants that the Compound, matched
placebo and Product conveyed to Myogen under Section 3.1(b) has been or shall be
manufactured in accordance with current Good Manufacturing Practices ("cGMP").
Other than the foregoing warranty, any Compound shall be conveyed "AS IS" and
"WITH ALL FAULTS," WITHOUT ANY OTHER WARRANTY OF ANY KIND WHATSOEVER, EXPRESS OR
IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR PARTICULAR
PURPOSE. Myogen shall be responsible for all testing, quality control and
certification of such Compound.

         3.2 ABBOTT EXCLUSIVITY. During the Term, and except as described in
Section 4.3(a), neither Abbott nor its Affiliates, shall directly or through
intermediaries, undertake any development or commercialization activities
related to Pharmaceutical Uses, [...***...]

4. FEASIBILITY/EVALUATION/DEVELOPMENT/MANUFACTURING/MARKETING/OTHER.

         4.1 FEASIBILITY/EVALUATION STUDIES. Myogen shall use commercially
reasonable efforts to evaluate the Compound in accordance with the Work Plan.
For purposes of this Agreement, the term "commercially reasonable efforts" shall
mean, in the case of Myogen, those efforts that would be expected in the
pharmaceutical industry of a company substantially similar to Myogen and, in the
case of Abbott, those efforts that would be expected in the pharmaceutical
industry of a company substantially similar to Abbott Laboratories, its parent
company. Myogen shall have sole responsibility for conducting and/or supervising
the feasibility and evaluation studies on the Compound as set forth in the Work
Plan. Myogen shall provide Abbott with summaries of the feasibility and
evaluation studies conducted by or on behalf of Myogen, including summaries of
reports and data generated under such studies, on a semi-annual basis (including
at any annual review meeting held pursuant to Section 4.2 below), and all such
information shall be treated as Myogen's Confidential Information.
Notwithstanding the foregoing, Abbott agrees to use commercially reasonable
efforts to complete, on behalf of Myogen, those feasibility and evaluation
studies listed on Exhibit C [...***...]. For all such studies that will be
performed by Abbott on behalf of Myogen, Myogen shall have the right to review
and approve all trial plans and protocols prior to initiation of any study, and
Myogen shall receive regular reports regarding the progress of such studies.
Periodically, as the progress of the studies may dictate, the Work Plan may be
amended upon mutual written agreement of the parties, and such amendments shall
be reflected in an amended Exhibit B. Recognizing that certain work to be
conducted on behalf of Myogen will be performed by one or more third parties and
recognizing that such work

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

(e.g., formulations) may involve the patented subject matter of such third
party, Myogen will use commercially reasonable efforts to (i) provide in its
license with the third party that the patented subject matter of such third
party may be sublicensed to Abbott in the event that the Compound and Product
are returned to Abbott under Sections 4.3(b) and 4.8; and (ii) negotiate a
[...***...] license/sublicense with such third party. In the event that Myogen
is unable to negotiate a [...***...] license/sublicense, Abbott agrees to assume
the [...***...] obligations thereunder if it elects to practice under such
license/sublicense following the return of the Compound and Product under
Sections 4.3(b) and 4.8. Myogen agrees to promptly provide Abbott with written
notice of the terms of any licenses entered into with third parties which
pertain to the Compound and/or Product.

         4.2 REVIEW. Beginning one month following the Effective Date and every
six (6) months thereafter while Myogen is developing the Compound, Myogen shall
provide Abbott with a written report reviewing the progress of the Work Plan and
the results of such work and studies remaining to be completed under the Work
Plan, which report shall be deemed Myogen Confidential Information. In the event
Abbott so requests, the parties shall meet in person once during each calendar
year to discuss these topics. The meeting shall be held at a mutually agreeable
time and location. Each party shall be responsible for its own costs of
attendance.

         4.3 CLINICAL DEVELOPMENT.

                  (a) Myogen shall use commercially reasonable efforts to
develop the Compound in accordance with the Work Plan. Myogen shall have sole
responsibility for designing, conducting and paying for the cost of the clinical
development of Product and shall use commercially reasonable efforts to conduct
such clinical development as set forth below. Except as set forth in Section 3.2
above, Abbott hereby agrees that it shall not undertake any research or
development related to Pharmaceutical Uses of the Compound during the Term,
except as may be necessary following the license granted to Abbott under Section
4.8 in the event of a termination of this Agreement under Sections 8.2, 8.3 or
8.4.

                  (b) In the event Myogen breaches a material obligation under
this Agreement, Abbott may then advise Myogen that Abbott believes that Myogen
has breached such material obligation and that Abbott is adversely impacted
thereby. Upon so advising Myogen, Abbott may initiate an alternative dispute
resolution procedure ("ADR") as set forth in Exhibit D, and request the ADR to
rule upon whether Myogen has breached any such material obligation. In the event
that the neutral party conducting such ADR renders a ruling that Myogen has
breached such material obligation and that Abbott was adversely impacted
thereby, and Myogen fails to comply with the terms of the neutral's ruling
within the time specified therein for compliance, or if such compliance cannot
be fully achieved by such date, Myogen has failed to commence

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

compliance and/or has failed to use diligent efforts to achieve full compliance
as soon thereafter as is reasonably possible, then Abbott's sole remedy shall be
(i) the right to terminate this Agreement and the licenses granted hereunder,
and to obtain from Myogen a license to Improvements under Section 4.8.

         4.4 COMMERCIALIZATION.

                  (a) Myogen shall use commercially reasonable efforts to
develop, register and commercialize Product in at least the following major
countries: [...***...] (each a "MAJOR COUNTRY"), using at least that level of
effort standard in the pharmaceutical industry that a pharmaceutical company of
Myogen's general size would use to commercialize a product similar to the
Product. It is the parties' expectation that Myogen will commercialize Product
in all commercially viable markets in addition to Major Countries within
[...***...] following First Commercial Sale of the Product. If, following such
[...***...] period, there remain markets where Myogen is not commercializing
Product which Abbott, in its reasonable estimation, believes are commercially
viable markets, then the parties shall meet within thirty (30) days of Abbott's
written notice for the purpose of developing a mutually agreeable action plan
for such under-served markets. If the parties are unable to agree on an action
plan, Abbott and its Affiliates shall have the right, upon notice to Myogen, to
sell the Product directly in each such country, by paying to Myogen or its
sublicensees [...***...] to which Abbott would otherwise be entitled if Myogen
were marketing the Product in such country. Myogen agrees to provide Product to
Abbott and its Affiliates for sale in each such country [...***...] and to
cooperate with Abbott by, among other things, working with Abbott and its
Affiliates to coordinate marketing and sales strategies consistent with Myogen's
global Product marketing strategies, clinical studies and the development of
selling and other materials necessary for the effective sale and marketing of
Product in a country.

                  (b) If there is any material disagreement between the parties
concerning whether commercially reasonable efforts towards commercialization
have been made with respect to a particular indication after Regulatory Approval
in a Major Country, then the matter may be submitted to ADR. If the neutral
party conducting such ADR makes a final determination that Myogen has failed to
use commercially reasonable efforts to develop, register and/or commercialize
Product in a Major Country, the neutral party shall provide Myogen with the
opportunity to undertake such activities and expenses as needed to correct the
failure. If Myogen fails to correct the failure within the time period
prescribed by the neutral party, then the neutral party may provide remedies for
failure to expend such efforts, which could include a requirement for Myogen to
expend additional efforts to make up for any failures, the grant of rights to
Abbott to sell Product in the under-served country, damages and/or termination
of the license rights in the applicable country.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  (c) If there is any material disagreement between the parties
concerning whether a market that is not a Major Country is commercially viable
such that Myogen should be commercializing Product in accordance with Section
4.4(a) hereof, or if Myogen reasonably believes that Abbott's selling of Product
in a particular country will have a substantial negative impact on Myogen's
local, regional or global commercial efforts, then the matter may be submitted
to ADR. If the neutral party conducting such ADR makes a final determination
that a market that is not a Major Country is commercially viable and that Myogen
should be commercializing Product in such market, the neutral party shall
provide Myogen with the opportunity to commercialize Product in such market. If
Myogen fails to so commercialize Product within the time period prescribed by
the neutral party, then the neutral may grant Abbott the right to sell Product
in the under-served country if the neutral party concludes that such sales
efforts by Abbott will not have a substantial negative impact on Myogen's local,
regional or global commercial efforts.

         4.5 MARKETING. Except as set forth in Section 4.4 above, Myogen shall
have sole responsibility for marketing Product, including entering into any
co-marketing and/or co-promotion arrangements. Myogen shall distribute all
Product samples in the United States in accordance with the Prescription Drug
Marketing Act.

         4.6 MANUFACTURING:

                           (a) As of the Effective Date, the parties contemplate
that Abbott or an Abbott Affiliate will manufacture Compound and/or Product and
supply Myogen with its requirements of Compound and/or Product during the Term
pursuant to a definitive Manufacturing Development and Supply Agreement to be
executed by the parties, subject to Myogen's right to qualify a second source to
manufacture Compound and/or Product and to receive up to [...***...] of its
annual requirements of Compound and/or Product from such second source and to
engage a third party manufacturer for finishing Compound and/or Product supplied
by Abbott in bulk form, as provided in Section 4.6(c) below. The Manufacturing
Development and Supply Agreement shall cover the manufacture and supply of
pre-clinical, clinical and/or commercial bulk active Compound and/or Product.
If, following good faith negotiations, the parties are unable to execute a
definitive Manufacturing Development and Supply Agreement within ninety (90)
days of the commencement of their negotiations, and Myogen elects to
self-manufacture Compound and/or Product, then the exclusive license granted
under Section 2.1 above shall be deemed to include the additional rights set
forth in Section 2.2 above. In such event, Abbott shall provide Myogen with the
manufacturing protocol for the Compound and/or Product, which protocol shall be
considered Abbott Confidential Information. All additional Know-How or Abbott
Confidential Information relating to raw materials or precursors to the
Compound, and all additional information and documentation, which are necessary
to make Compound and/or Product, shall be transferred in a timely fashion to
Myogen as mutually agreed by the parties [...***...].

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  (b) If the parties are unable to negotiate a definitive
Manufacturing Development and Supply Agreement as provided above and Myogen
elects to negotiate terms and conditions with a third party manufacturer of
Compound and/or Product, Myogen shall, prior to executing a definitive agreement
with such third party, provide Abbott with a summary of the material terms and
conditions and allow Abbott the opportunity to meet or beat such terms and
conditions, taken as a whole, with all such material terms and conditions
considered. If Abbott fails to meet or beat such terms and conditions within
thirty (30) days of its receipt, Myogen shall be free to execute a definitive
agreement for the manufacture and supply of Compound and/or Product with such
third party and, in such event, the additional rights set forth in Section 2.3
above shall be granted to Myogen for the purpose of allowing the third party to
manufacture and supply Compound and/or Product to Myogen. In addition, Abbott
shall provide Myogen with the manufacturing protocol for the Compound and/or
Product, which protocol shall be considered Abbott Confidential Information. All
additional Know-How or Abbott Confidential Information relating to raw materials
or precursors to the Compound, and all additional information and documentation,
which are necessary to have made Compound and/or Product, shall be transferred
in a timely fashion to Myogen as mutually agreed by the parties [...***...].
Myogen may provide the manufacturing protocol to the third party manufacturer
under terms which provide for the protection of such Abbott Confidential
Information.

                  (c) Myogen shall have the right, at any time, to qualify a
second source (including itself) to manufacture up to [...***...] of its annual
requirements of Compound and/or Product and to engage a third party manufacturer
for finishing Compound and/or Product supplied by Abbott in bulk form. In either
event, the additional rights set forth in Sections 2.2 and 2.3 above shall be
granted to Myogen solely for purposes of allowing such additional sources to
manufacture and/or finish Compound and/or Product for Myogen, as the case may
be. Myogen shall be solely responsible for all costs and expenses necessary to
qualify such second source. Abbott shall provide Myogen with the manufacturing
protocol for the Product, which protocol shall be considered Abbott Confidential
Information. All additional Know-How or Abbott Confidential Information relating
to raw materials or precursors to the Compound, and all additional information
and documentation, which are necessary to make or have made Compound and/or
Product, shall be transferred in a timely fashion to Myogen as mutually agreed
by the parties and at no cost to Myogen. Myogen may provide the manufacturing
protocol to the second manufacturing source under terms which provide for the
protection of such Abbott Confidential Information.

         4.7 SUBLICENSING. Myogen may sublicense its rights under this
Agreement, without obtaining Abbott's prior written consent. Each sublicense
shall be in writing and shall include provisions acknowledging that such
sublicense is subject to the license granted Myogen under this Agreement, that
each sublicensee shall make reports and keep

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

and maintain records of sales to at least the same extent as required under this
Agreement, allowing Abbott the same access and audit rights permitted under this
Agreement, and that such sublicense shall be automatically terminated upon
termination of this Agreement. Myogen shall remain primarily liable for the
performance of sublicensees. Myogen shall provide Abbott with a copy of each
sublicense agreement.

         4.8 IMPROVEMENTS. All Improvements and all new patents which relate to
the Compound or the Product which come into existence during the Term and which
relate to or are derived from work conducted by or on behalf of Myogen or its
Affiliates or sublicensees relating to the Compound without any contribution by
Abbott, its Affiliates, contractors, or agents, shall be deemed the property of
Myogen. Provided, however, in the event this Agreement is terminated by Abbott
for any reason, as set forth in Article 8, or by Myogen under Section 8.2, all
such Improvements shall be exclusively licensed to Abbott solely for use with
the Compound and Product [...***...] and Myogen retains all rights in and to any
such Improvements for any and all other uses.

5. FINANCIALS.

         5.1 DEVELOPMENT COST REIMBURSEMENT. Myogen shall reimburse Abbott for
[...***...] of the development costs incurred by Abbott and its Affiliates. Such
reimbursement shall be made over a [...***...] as follows: (i) a payment of
[...***...]; (ii) a payment of [...***...] on [...***...], together with accrued
interest from and after the Effective Date at [...***...]; and (iii) a payment
of [...***...] on [...***...], together with accrued interest from and after the
Effective Date at [...***...].

         5.2 EXECUTION FEE. Myogen shall pay to Abbott [...***...] on the
Effective Date.

         5.3 MILESTONES. Myogen shall make the following milestone payments to
Abbott within twenty (20) days of the occurrence of the following events,
regardless of whether or not Myogen has sublicensed any of its rights under this
Agreement:

<Table>
<Caption>
         MILESTONE                                                      PAYMENT
         ---------                                                      -------

<S>                                                                     <C>
         Initiation of Phase III Clinical Study*                        [...***...]
         NDA Filing in U.S.*                                            [...***...]
         NDA Filing in [...***...] Major Countries [...***...]          [...***...]
</Table>

*If CHF is the first indication where a Phase III Clinical Study is initiated or
an NDA is filed, the full payment amounts indicated above shall be due with
respect to CHF. If a Phase III Clinical Study is initiated or an NDA is filed
for CRF, PAH or any other indication before CHF, then the payment amounts due
shall be one-half the amounts

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

indicated above for each such indication, subject in all cases to a maximum
total payment of (i) [...***...] for initiation of Phase III Clinical Studies
for all indications; (ii) [...***...] for NDA filings in the U.S. for all
indications; and (iii) [...***...] for NDA filings in [...***...] Major
Countries [...***...] for all indications.

<Table>
<Caption>
                  MILESTONE                            PAYMENT
                  ---------                            -------
<S>                                                 <C>

         Regulatory Approval in U.S. for CHF         [...***...]
         Regulatory Approval in U.S. for CRF         [...***...]
         Regulatory Approval in U.S. for PAH         [...***...]
</Table>

If Regulatory Approval is obtained in the U.S. for any other indication prior to
obtaining Regulatory Approval for CHF, CRF and PAH, then the milestone payable
for each such other indication shall be [...***...], provided that the maximum
total milestone payments for obtaining U.S. Regulatory Approval for all
indications shall not exceed [...***...].

<Table>
<Caption>
         MILESTONE                                                      PAYMENT
         ---------                                                      -------

<S>                                                                     <C>
         Regulatory Approval in [...***...] Major Countries
                  [...***...] for CHF**                                 [...***...]
         Regulatory Approval in [...***...] Major Countries
                  [...***...] for CRF**                                 [...***...]
         Regulatory Approval in [...***...] Major Countries
                  [...***...] for PAH**                                 [...***...]
</Table>

** In the event a centralized filing and Regulatory Approval process has
replaced the requirement to file in and receive Regulatory Approval from each
Major Country [...***...], then such a single filing, and receipt of Regulatory
Approval from [...***...], together with receipt of pricing approval in
[...***...] Major Countries [...***...], shall supercede the requirement to
obtain Regulatory Approval in [...***...] Major Countries [...***...].

If Regulatory Approval is obtained in [...***...] Major Countries [...***...]
(or through a single filing as set forth in the preceding paragraph) for any
other indication prior to obtaining Regulatory Approval for CHF, CRF and PAH,
then the milestone payable for each such other indication shall be [...***...],
provided that the maximum total milestone payments for obtaining [...***...]
Regulatory Approval for all indications shall not exceed [...***...].

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

THE MAXIMUM TOTAL MILESTONE PAYMENTS DUE ABBOTT IF ALL OF THE FOREGOING
MILESTONES ARE MET WILL TOTAL [...***...].

         5.4 ROYALTY PAYMENTS.

                  (a) ROYALTY RATE AND ROYALTY PERIOD. Beginning with
[...***...] Myogen shall pay to Abbott a royalty on annual aggregate worldwide
Net Sales of all Product for all Pharmaceutical Uses in accordance with the
following schedule:

<Table>
<Caption>
                   ANNUAL NET SALES                     ROYALTY
                   ----------------                     -------

<S>                                                     <C>
                   [...***...]                          [...***...]
</Table>

The obligation of Myogen to pay a full royalty to Abbott shall be on a
country-by-country basis and shall continue with respect to Product manufactured
or sold in a country until [...***...] ("ROYALTY PERIOD"). [...***...]

                  (b) REDUCED ROYALTY PERIOD. Upon the end of the Royalty Period
in any country of the Territory on a country-by-country basis, Myogen shall have
an exclusive, perpetual and irrevocable license under Abbott's Technology in
such country of the Territory, with all of the rights granted under Article 2
hereof, except that, for so long as Product continues to be sold in such country
by Myogen, Myogen shall pay to Abbott a reduced royalty equal to [...***...] of
the royalty that would otherwise be due during the Royalty Period (the "REDUCED
ROYALTY PERIOD").

The royalty payable for the Reduced Royalty Period shall be calculated by
[...***...]

                  (c) ROYALTY REPORTS AND PAYMENTS. Beginning with the First
Commercial Sale anywhere in the Territory, within forty-five (45) days after the
end of each calendar quarter, Myogen shall prepare and deliver to Abbott a
report detailing the calculation of Net Sales in the Territory, on a
country-by-country basis, for such just ended quarter along with the calculation
of royalties due thereon pursuant to Sections 5.4(a) and (b) above. Each report
shall be accompanied by full payment in U.S. dollars of the royalties shown
thereon to be due. In the event that conversion from foreign currency is
required in calculating a royalty payment hereunder, the exchange rate used
shall be the ratio in effect at the end of the last business day of the
applicable quarter for which royalties are calculated, as reported by The Wall
Street Journal, or a substantially similar global publication if The Wall Street
Journal is no longer published.

                  (d) BOOKS AND RECORDS/AUDIT RIGHTS. Myogen shall keep books
and records accurately showing all Products manufactured, used or sold under the
terms of this Agreement. The relevant portions of such books and records shall
be open to inspection by representatives of Abbott, at Abbott's cost, solely for
the purposes of determining the correctness of the royalties payable under this
Agreement. Such audit, conducted no more than one time per calendar year, shall
be during normal business

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

hours after reasonable advance notice and subject to suitable confidentiality
provisions. In the event an audit shows a deficiency to be due, Myogen shall
immediately pay such deficiency along with the reasonable costs and expenses of
the audit if the deficiency is more than five percent (5%) of the amount due
during such audited period. If the audit shows that an excess was paid, Myogen
shall be entitled to deduct the amount of such excess from the payment due for
the next calendar quarter. Such books and records shall be preserved for a
period of at least three (3) years after the date of the royalty payment to
which they pertain, and no audit may be conducted with respect to royalties due
in any calendar year that is more than two (2) years preceding the calendar year
in which the audit is being conducted. Books and records for a given calendar
year may only be audited once.

                  (e) WITHHOLDING TAXES ON ROYALTIES. Where any sum due to be
paid to Abbott hereunder is subject to any withholding or similar tax, the
parties shall use all reasonable efforts to do all such acts and things and to
sign all such documents as will enable them to take advantage of any applicable
double taxation agreement or treaty. In the event there is no applicable double
taxation agreement or treaty, or if an applicable double taxation agreement or
treaty reduces but does not eliminate such withholding or similar tax, Myogen
shall pay such withholding or similar tax to the appropriate government
authority, deduct the amount paid from the amount due Abbott and secure and send
to Abbott the best available evidence of such payment sufficient to enable
Abbott to obtain a deduction for such withheld taxes or obtain a refund thereof.

6. REPRESENTATIONS/WARRANTIES.

         6.1 REPRESENTATIONS AND WARRANTIES OF ABBOTT. Abbott represents and
warrants that:

                  (a) it is duly organized, validly existing and in good
standing under the laws of Germany, that it has full corporate power and
authority to enter into this Agreement and to carry out its provisions, and that
there are no outstanding agreements, assignments or encumbrances in existence
that are inconsistent with the provisions of this Agreement;

                  (b) it is duly authorized to execute and deliver this
Agreement and to perform its obligations hereunder and that the execution,
delivery and performance of this Agreement by it does not require the consent,
approval or authorization of or notice, filing or registration with any
governmental agency or Regulatory Authority;

                  (c) as of the Effective Date, to the best of Abbott's
knowledge, (i) it has sufficient rights under the Abbott Technology necessary to
grant the rights specified in this Agreement and to perform its obligations
hereunder; (ii) there are no claims,

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

judgments or settlements against or owed by it relating to the Abbott
Technology; and (iii) the exercise of Myogen's rights to the Compound under this
Agreement or Myogen's use of the Abbott Technology under this Agreement will not
infringe any intellectual property rights of a third party; and

                  (d) as of the Effective Date, to the best of Abbott's
knowledge, (i) none of the Patents are invalid or unenforceable, (ii) it has
complied in all material respects with all applicable laws and regulations in
connection with the preparation and submission of any filings with any
Regulatory Authority; (iii) it has filed with applicable Regulatory Authorities
all required and material notices, supplemental applications and annual or other
reports, including adverse experience reports, with respect to the Compound; and
(iv) there is no pending or overtly threatened action by the Regulatory
Authorities that will have a material adverse effect on the Regulatory Approval
of the Compound or any products.

         6.2 REPRESENTATIONS AND WARRANTIES OF MYOGEN. Myogen represents and
warrants that it is duly organized, validly existing and in good standing under
the laws of Delaware, that it has full corporate power and authority to enter
into this Agreement and to carry out its provisions, and that there are no
outstanding agreements, assignments or encumbrances in existence that are
inconsistent with the provisions of this Agreement. Myogen further represents
and warrants that it is duly authorized to execute and deliver this Agreement
and to perform its obligations hereunder, and that the execution, delivery and
performance of this Agreement by it does not require the consent, approval or
authorization of or notice, filing or registration with any governmental agency
or Regulatory Authority.

         6.3 INDEMNIFICATION BY MYOGEN. Myogen shall indemnify and hold Abbott,
its Affiliates and their directors, officers, employees and agents harmless from
and against any and all liabilities, actions, suits, claims, demands,
prosecutions, damages, costs, expenses or money judgments finally awarded
(including reasonable legal fees) (collectively, "LIABILITIES") incurred by or
instituted or rendered against Abbott to the extent such Liabilities result from
a third party claim arising from product liability claims or from the willful
misconduct or the negligent acts or omissions of Myogen or its Affiliates or
Myogen's material breach of this Agreement, except to the extent such third
party claims arise out of the negligence or willful misconduct of Abbott, its
Affiliates and their directors, officers, employees and agents, or the material
breach of this Agreement or the Manufacturing Development and Supply Agreement
by Abbott, its Affiliates and their directors, officers, employees and agents,
and provided that Abbott gives Myogen prompt notice in writing of any such claim
or lawsuit and permits Myogen to undertake sole control of the defense and
settlement thereof at Myogen's expense. In any such claim or lawsuit:

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  (a) Abbott will cooperate in the defense by providing access
to witnesses and evidence available to it. Abbott shall have the right to
participate, at its expense, in any defense to the extent that in its reasonable
judgment Abbott may be prejudiced by Myogen's sole defense thereof.

                  (b) With respect to this Agreement, Abbott shall not settle,
offer to settle or admit liability in any claim or suit in which Abbott intends
to seek indemnification by Myogen without the written consent of a duly
authorized officer of Myogen.

         6.4 INDEMNIFICATION BY ABBOTT. Abbott shall indemnify and hold Myogen,
its Affiliates and their directors, officers, employees and agents harmless from
and against any and all Liabilities, incurred by or instituted or rendered
against Myogen to the extent such Liabilities result from a third party claim
arising from the willful misconduct or the negligent acts or omissions of Abbott
or its Affiliates or Abbott's material breach of this Agreement, except to the
extent such third party claims arise out of the negligence or willful misconduct
of Myogen, its Affiliates and their directors, officers, employees and agents,
or the material breach of this Agreement by Myogen, its Affiliates and their
directors, officers, employees and agents, and provided that Myogen gives Abbott
prompt notice in writing of any such claim or lawsuit and permits Abbott to
undertake sole control of the defense and settlement thereof at Abbott's
expense. In any such claim or lawsuit:

                  (a) Myogen will cooperate in the defense by providing access
to witnesses and evidence available to it. Myogen shall have the right to
participate, at its expense, in any defense to the extent that in its reasonable
judgment Myogen may be prejudiced by Abbott's sole defense thereof.

                  (b) With respect to this Agreement, Myogen shall not settle,
offer to settle or admit liability in any claim or suit in which Myogen intends
to seek indemnification by Abbott without the written consent of a duly
authorized officer of Abbott.

         6.5 REPORTABLE OCCURRENCES. Each party warrants that it shall advise
the other promptly of any occurrence which is reported or reportable by it to
the Regulatory Authorities relating in any way to the Compound or the Product.

         6.6 LIMITATION. EXCEPT FOR THE EXPRESS WARRANTIES IN THIS ARTICLE 6,
NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, IN FACT OR BY OPERATION
OF LAW, STATUTORY OR OTHERWISE. EACH PARTY SPECIFICALLY DISCLAIMS ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT FOR
VIOLATIONS OF ARTICLE 7 AND AMOUNTS

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

FINALLY AWARDED FOR INDEMNIFICATION FOR THIRD PARTY LIABILITIES UNDER SECTIONS
6.3 AND 6.4 ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY HERETO OR TO
ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
(INCLUDING LOST OR ANTICIPATED PROFITS RELATING TO THE SAME) ARISING FROM ANY
CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT
(INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF
SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME.

7. CONFIDENTIALITY AND NON-DISCLOSURE.

         7.1 NONDISCLOSURE. Neither party shall use or disclose any Confidential
Information received by it from the other party pursuant to this Agreement
without the prior written consent of the other. This obligation will continue
for a period of seven (7) years after termination of this Agreement or
expiration of the Term, whichever is earlier. Subject to the exception
immediately below, Abbott shall hold in confidence and shall not directly or
indirectly disclose or provide to any third party information pertaining to the
Compound or Abbott Technology without Myogen's prior written consent. The
parties recognize in Section 3.2 of this Agreement that Abbott may be utilizing
Compound and Abbott Technology in certain limited circumstances, including, but
not limited to, non-Pharmaceutical Uses and for internal research purposes.
Abbott shall be permitted to disclose information pertaining to the Compound and
the Abbott Technology in such circumstances only if the recipient of such
information is under a duty of confidentiality to Abbott, and further, provided
that no such disclosure of such information shall be made for Pharmaceutical
Uses, nor shall Confidential Information of Myogen be disclosed.

         7.2 RESTRICTION. Each party shall restrict dissemination of
Confidential Information to those of its employees, contractors, agents and
sublicensees (if any) who have an actual need to know and have a legal
obligation to protect the confidentiality of such Confidential Information. All
Confidential Information disclosed by one party to the other shall remain the
sole property of the disclosing party and neither party shall obtain any right
of any kind to the Confidential Information disclosed, except as granted under
this Agreement.

         7.3 RESTRICTION EXEMPTIONS. Nothing contained in this Article 7 shall
be construed to restrict the parties from using or disclosing Confidential
Information solely to the extent and solely as required:

                  (a) for regulatory, tax or customs reasons;

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

             (b) by court order or other governmental order or request. provided
in each case the party disclosing information promptly informs the other and
uses its best efforts to limit the disclosure and to maintain confidentiality to
the maximum extent possible and permits the other party to attempt by
appropriate legal means to limit such disclosure; or

             (c) to perform acts permitted by this Agreement, including (i)
disclosure by Myogen to third parties undertaking feasibility and evaluation
studies, clinical trials and the like on behalf of Myogen, so long as such third
parties are under a legal obligation to Myogen to protect the confidentiality of
such Confidential Information, or (ii) disclosure by Myogen to sublicensees, so
long as such sublicensees are under a legal obligation to Myogen to protect the
confidentiality of such Confidential Information, or (iii) disclosure by Myogen
in connection with the marketing and commercial sale of Product, or (iv)
disclosure by Myogen to the extent required by law.

8. TERM AND TERMINATION.

         8.1 This Agreement shall continue in effect unless and until terminated
as provided in this Section 8 or in Section 4.3(b). Upon the end of the Royalty
Period in any country of the Territory, Myogen shall have an exclusive,
perpetual and irrevocable license under Abbott's Technology, with all of the
rights granted under Article 2 hereof, and without any further obligation to
Abbott, except for the payment obligations accruing prior to such date and the
indemnification obligations under Section 6.3, and except for any obligation to
pay [...***...], as provided in Section 5.4(b) hereof.

         8.2 If Myogen determines in its reasonable scientific and commercial
judgment that the Compound does not have an acceptable profile or a reasonable
likelihood of commercial success, or that it is economically or technically
impractical for Myogen to continue developing and marketing the Product, Myogen
shall have the right to terminate this Agreement upon ninety (90) days written
notice, at the end of which the termination shall be effective. Upon such
termination, Myogen shall pay all payments and royalties which may have become
due prior to the effective date of such termination, and Myogen shall assign and
deliver, and Abbott shall be entitled to retain for its own use, all studies and
information relating to the Compound and shall be granted a license to all
Improvements as set forth in Section 4.8 hereof.

         8.3 Either party may terminate this Agreement by giving to the other
party prior written notice of not less than thirty (30) days in the case of a
monetary breach and of not less than ninety (90) days in the event the other
party shall commit a non-monetary material breach of this Agreement, and such
breaching party shall fail to cure, or commence action to cure, such breach
during such thirty (30) or ninety (90) day period, as applicable. In the case of
a non-monetary breach, the cure period may be extended for such longer period as
may reasonably be necessary if cure is not reasonably possible

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

within the initial ninety (90) day period, provided the breaching party
continues its diligent efforts to cure. No such cancellation and termination
shall release the breaching party from any obligations hereunder incurred prior
thereto. In the event of a dispute whether a material breach has occurred, the
existence of material breach shall be determined using the ADR procedure set
forth in Exhibit D. A party's right to terminate this Agreement shall only apply
if the breaching party fails to cure such breach in the manner required by the
final judgment of the ADR hearing. In the event that this Agreement is
terminated for Myogen's material breach, Abbott shall be entitled to retain
[...***...], and Myogen shall assign and deliver, and Abbott shall be entitled
to retain for its own use, all studies and information relating to the Compound
and Abbott shall be granted a license to all Improvements generated hereunder as
set forth in Section 4.8 hereof. In the event that this Agreement is terminated
for Abbott's material breach, Myogen shall not be liable for payments not yet
due and payable under Article 5 hereof, and Myogen shall be entitled to retain
for its own use all studies, information and Improvements generated hereunder
and no license to Improvements shall be granted to Abbott under Section 4.8
hereof.

         8.4 Either party may terminate this Agreement on thirty (30) days
notice if the other party passes a resolution or the court makes an order for
its winding up; or has a receiver or administrator appointed over its business
or all of its assets; or is or becomes bankrupt; or ceases its business
operations. In the event that this Agreement is terminated under this Section
8.4, subject to the other terms of this Agreement, the terminating party shall
be entitled to the assignment and delivery of, and shall be entitled to retain
for its own use all studies, information and Improvements (subject to the
license set forth in Section 4.8 as it concerns Abbott) generated hereunder.
Notwithstanding the bankruptcy or insolvency of Abbott or the impairment of
performance by Abbott of its obligations under this Agreement as a result of
bankruptcy or insolvency of Abbott, Myogen shall be entitled to retain the
licenses granted herein, without any further obligation to Abbott other than the
payment obligations under Article 5.

         8.5 Termination of this Agreement shall be without prejudice to any
rights of either party against the other which may have accrued up to the date
such termination becomes effective.

         8.6 All causes of action accruing to either party under this Agreement
shall survive expiration or termination of this Agreement for any reason.

         8.7 Upon any termination or expiration of this Agreement, each party
shall promptly return to the other party all written Confidential Information of
the other party, and all copies thereof (retaining one copy of the Confidential
Information of the other in its confidential files for archival purposes only),
which is not covered by a paid-up license or other rights specified herein
surviving such termination or expiration.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

9. INFRINGEMENT OF PATENTS BY THIRD PARTY. In the event of an actual or
suspected infringement of a Patent by a third party, the following shall apply:

         9.1 NOTICE. Each party shall give the other written notice if one of
them becomes aware of any infringement by a third party of any Patent. Upon
notice of any such infringement, the parties shall promptly consult with one
another with a view toward reaching agreement on a course of action to be
pursued.

         9.2 ABBOTT'S RIGHT TO BRING INFRINGEMENT ACTION.

                  (a) ABBOTT ELECTION. If a third party infringes any Patent,
Abbott shall have the right, but not the obligation, to institute and prosecute
an action or proceeding to abate such infringement and to resolve such matter by
settlement or otherwise.

                           (i) Abbott shall notify Myogen of its intention to
bring an action or proceeding prior to filing the same and in sufficient time to
allow Myogen the opportunity to discuss with Abbott the choice of counsel for
such matter. Abbott shall keep Myogen timely informed of material developments
in the prosecution or settlement of such action or proceeding. Abbott shall be
responsible for all fees and expenses of any action or proceeding against
infringers which Abbott initiates. Myogen shall cooperate fully [...***...] by
joining as a party plaintiff if reasonably requested to do so by Abbott, if
Myogen elects to join as a co-plaintiff or party plaintiff, or if required to do
so by law to maintain such action or proceeding and by executing and making
available such documents as Abbott may reasonably request. Myogen may be
represented by counsel in any such legal proceedings, [...***...].

                           (ii) If Abbott elects not to exercise such right, and
the parties disagree on the utility of bringing an action against an alleged
infringer, then the parties shall submit their disagreement to a mutually
agreeable third party attorney for resolution. If the third party attorney
decides that an action should be brought, then Abbott shall be obligated to
institute an action or proceeding in accordance with Section 9.2(a)(i) above. If
the third party attorney decides that an action should not be brought, then no
action shall be brought by either party unless Abbott later elects to institute
such an action or proceeding (or Abbott delegates such right to Myogen in
accordance with Section 9.2(a)(iii) below).

                           (iii) If Abbott so elects, Abbott may delegate to
Myogen the right to institute and prosecute an action or proceeding to abate
such infringement and to resolve such matter by settlement or otherwise. Abbott
shall cooperate fully by joining as a party plaintiff if reasonably requested to
do so by Myogen or if required to do so by law to maintain such action and by
executing and making available such documents as Myogen may reasonably request.
Abbott may be represented by counsel in any such action, at its own expense.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  (b) ABBOTT'S USE OF PROCEEDS. All amounts of every kind and
nature recovered from an action or proceeding of infringement brought by Abbott
shall belong to Abbott, and shall be used first to reimburse Abbott for its
documented and actual costs of prosecution, including attorneys' fees, expert
fees and all other related expenses, second to reimburse Myogen for its
documented and actual costs if it is represented by counsel in the proceeding.
The balance of the amount shall belong to Abbott if the amount awarded
represents a royalty, except to the extent that the royalty is in excess of the
royalty payable to Abbott under Section 5.4(a) hereof, in which case such excess
shall be split by the parties 50/50. Notwithstanding the foregoing, if the
balance of the amount awarded represents lost profits, and if Myogen joined as a
co-plaintiff or a party plaintiff to the action or proceeding of infringment
brought by Abbott pursuant to Section 9.2(a)(i) above, then Myogen shall be
entitled to the amount of damages allocated as lost profits, and the balance
shall belong to Abbott. Any exemplary or other damages awarded shall belong to
Abbott.

                  (c) MYOGEN'S USE OF PROCEEDS. All amounts of every kind and
nature recovered from an action or proceeding of infringement brought by Myogen
shall belong to Myogen, and shall first be used to reimburse Myogen for its
documented and actual costs of prosecution, second to reimburse Abbott for its
documented and actual costs if it is represented by counsel in the proceedings,
and the balance shall be considered Net Sales under this Agreement and subject
to royalty obligation under Section 5.4.

10. INFRINGEMENT OF THIRD PARTY RIGHTS; MYOGEN DEFENSE OF SUIT. If Abbott, its
Affiliates, Myogen, its Affiliates, sublicensees, distributors or other
customers are sued or threatened with suit by a third party alleging
infringement in one or more countries of the Territory of patents or other
intellectual property rights that are alleged to cover the manufacture, use,
sale, import, export or distribution of one or more Products, Abbott or Myogen,
whichever is relevant, will promptly notify the other in writing and provide a
copy of the lawsuit or claim. Myogen shall control the defense in any such claim
or suit. Myogen shall keep Abbott timely informed of material developments in
the defense of such claim or suit. If Myogen expends any amounts in connection
with any third party claim of infringement or misappropriation, or is required
to pay a royalty or other amount to a third party for the manufacture, use,
sale, import, export or distribution of one or more Products in the Territory as
a result of a final judgment or settlement, such amounts shall be fully
deductible by Myogen from the milestones and/or royalties payable and accruing
to Abbott thereafter under Section 5.4, but only where such claim, judgment or
settlement arises out of Myogen's practice of a Patent or use of the Abbott
Technology pursuant to the license granted under Article 2 of this Agreement.
Abbott shall fully cooperate with Myogen in the defense of any such action at
Abbott's expense. Myogen shall have the right to settle any such suit, including
the right to grant one or more sublicenses with Abbott's prior written approval,
which approval shall not unreasonably be withheld, provided that Myogen shall
not otherwise have the right to surrender, limit

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

or adversely affect any rights to the Patents. The terms of this Article 10
shall not apply to or affect Abbott's indemnity obligations for a breach of
Section 6.1(c).

11. PATENT PROSECUTION AND MAINTENANCE; PATENT COSTS; PATENT TERM EXTENSION.

         11.1 DISCLOSURE OF PATENTS/APPLICATIONS TO MYOGEN. Within thirty (30)
days of Myogen's request, Abbott shall provide Myogen a list of Patents and
patent applications in a given Patent family. If, following Myogen's receipt of
such list(s), Myogen requests additional information, Abbott shall provide to
Myogen the complete text of, and all other information in its possession or
control directly related to (a) all patent applications included in the given
Patent family filed anywhere in the Territory; and (b) all patents included in
the given Patent family as well as all information in Abbott's, its Affiliates
and its patent counsel's possession concerning the institution or possible
institution of any interference, opposition, reexamination, reissue, revocation,
nullification or any official proceeding involving an issued patent included in
the given Patent family anywhere in the Territory.

         11.2 PROSECUTION AND MAINTENANCE. Abbott shall be solely responsible
for the preparation, filing, prosecution and maintenance of the Patents (except
for the case family including [...***...] which is the responsibility of BASF
AG) in Abbott's name, including oppositions and interferences, subject to
Myogen's right to assume such duties in the event Abbott reasonably fails to
adequately prepare, file, prosecute and maintain the Patents. Abbott and Myogen
shall consult and cooperate with each other, and Abbott shall keep Myogen
reasonably informed with respect to the prosecution and maintenance of the
Patents hereunder, including the case family which is the responsibility of BASF
AG. In this regard Abbott shall exercise its rights under its license from BASF
AG for these patent rights such that Myogen shall have the opportunity to
participate in the preservation of these patent rights if it chooses to do so.
Abbott will provide Myogen with copies of all material documents received or
prepared by Abbott in the prosecution and maintenance of the Patents. Abbott
shall provide copies in a timely manner to allow Myogen an opportunity, if it so
elects, to review and comment on Abbott's proposed patent strategy. Inasmuch as
the Patents cover other compounds not licensed to Myogen hereunder, Abbott
warrants that it will not take any action with respect to the Patents which
would have a material adverse effect on the patent coverage of the Compound.

         11.3 PATENT EXTENSIONS. Abbott shall have the right and sole
responsibility for obtaining patent term extensions under the provisions of 35
USC Paragraph 156 for any U.S. Patent and for non-U.S. Patents under similar
provisions of law of other countries involving a Product which has obtained
Regulatory Approval. Myogen shall cooperate with Abbott and provide Abbott with
all necessary information to obtain such extensions.

12. TRADEMARK. Myogen may select any Trademark or Trademarks for the Product in
the Territory. All costs related to the selection and maintenance of the
Trademark(s)

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

shall be borne by Myogen. The Trademark(s) shall be owned by Myogen, and Abbott
shall have no claims or rights in or to the Trademark(s), except such right as
may be necessary for Abbott to commercialize Product following a termination
under Sections 8.2, 8.3 or 8.4 above.

13. IMPROVEMENTS. All Improvements made solely by Myogen and/or its Affiliates
hereunder shall be the sole and exclusive property of Myogen. All Improvements
made solely by Abbott and/or its Affiliates shall become part of Abbott's
Technology, subject to the license to Myogen set forth in Article 2 hereof. All
Improvements made jointly by employees or others acting on behalf of Abbott and
Myogen (or their Affiliates) hereunder shall be jointly owned by Abbott and
Myogen, without a duty of accounting to the other, to the extent such
individuals would be considered "joint inventors" within the meaning of the U.S.
patent laws. Each party shall take all necessary actions, including executing
documents of assignment, to vest title to all jointly owned Improvements
(including all intellectual property rights therein) with both parties. With
respect to patents resulting from Improvements made jointly by the parties, the
parties shall select a mutually agreeable third party attorney to prepare, file,
prosecute and maintain such patents. The third party attorney shall consult and
apprise each party equally and both parties shall share 50/50 the costs and fees
of employing such third party attorney. Abbott's interest in such Improvements
shall be subject to the license granted to Myogen under Article 2 hereof and
subject to the terms and conditions of this Agreement. The provisions of this
Article 13 are subject to the rights of the terminating party under Article 8
hereof.

14. MISCELLANEOUS.

         14.1 FORCE MAJEURE. If the performance by either party of any of its
obligations under this Agreement shall be prevented by circumstances beyond its
reasonable control which could not have been avoided by the exercise of
reasonable diligence, then such party shall be excused from the performance of
that obligation for the duration of the event. The affected party shall promptly
notify the other party in writing should such circumstances arise, give an
indication of the likely extent and duration thereof, and shall use commercially
reasonable efforts to resume performance of its obligations as soon as
practicable.

         14.2 NOTICES. Any notice required to be given or made under this
Agreement by one of the parties hereto to the other shall be in writing, by
personal delivery, registered U.S. mail or overnight courier, addressed to such
other party at its address indicated below, or to such other address as the
addressee shall have last furnished in writing to the addressor and shall be
effective upon the date of receipt.

                  If to Myogen:             Myogen, Inc.
                                            7577 W. 103rd Avenue
                                            Westminster, CO 80021-5426
                                            Attn: President

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  With a copy to:           Cooley Godward LLP
                                            380 Interlocken Crescent
                                            Suite 900
                                            Broomfield, CO 80021-8023
                                            Attn: Steven N. DuPont, Esq.

                  If to Abbott:             Abbott Laboratories
                                            100 Abbott Park Road
                                            Dept. 309; Bldg. AP30
                                            Abbott Park, IL 60064-3537
                                            Attn: Senior Vice President,
                                                  Pharmaceutical Operations

                  With a copy to:           Abbott Laboratories
                                            100 Abbott Park Road
                                            Dept. 364; Bldg. AP6D
                                            Abbott Park, IL 60064-6032
                                            Attn: Senior Vice President,
                                                  Secretary and General Counsel

         14.3 APPLICABLE LAW/COMPLIANCE. This Agreement shall be governed by and
construed in accordance with the laws of the State of Illinois, excluding its
conflict of laws provision. Each party hereto shall comply with all applicable
laws, rules, ordinances, guidelines, consent decrees and regulations of any
federal, state or other governmental authority.

         14.4 ENTIRE AGREEMENT. This Agreement and the attachments (Exhibits)
contain the entire understanding of the parties with respect to the subject
matter hereof. All express or implied agreements and understandings, either oral
or written, heretofore made are expressly merged in and made a part of this
Agreement. This Agreement may be amended, or any term hereof modified, only by a
written instrument duly executed by both parties hereto. The Heads of Agreement
between Myogen and Knoll AG (predecessor in interest to Abbott) dated November
14, 2000, is hereby terminated upon mutual execution of this Agreement.

         14.5 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

         14.6 SEVERABILITY/HEADINGS. If any provision of this Agreement is
deemed unenforceable, the remainder of the Agreement will not be affected and,
if appropriate, the parties will attempt to replace the unenforceable provision
with a new provision that, to the extent possible, reflects the parties'
original intent. The captions and headings used in this Agreement are for
reference only and are not to be construed in any way as terms or used to
interpret the provisions of this Agreement.

         14.7 ASSIGNMENT. Neither party may without written approval of the
other assign this Agreement or transfer its interest or any part thereof under
this Agreement to any third party except that (i) either party may assign this
Agreement without consent to a third party that acquires all or substantially
all of the business to which this Agreement pertains, or, (ii) either party may
assign this Agreement in whole or part to any Affiliate of that party and such
party hereby guarantees the performance by such Affiliate.

         14.8 DISPUTE RESOLUTION. The parties hereto shall attempt to settle any
dispute arising out of or relating to this Agreement in an amicable way. Except
for claims for injunctive or other equitable relief, which may be brought in any
court of competent jurisdiction, any controversy, claim or right of termination
for cause which may arise under, out of, in connection with, or relating to this
Agreement, or any breach thereof, shall be settled according to the Alternative
Dispute Resolution provisions attached hereto as Exhibit D.

         14.9 INDEPENDENT CONTRACTOR. It is understood that both parties hereto
are independent contractors and engage in the operation of their own respective
businesses and neither party hereto is to be considered the agent of the other
party for any purpose whatsoever and neither party has any authority to enter
into any contract or assume any obligation for the other party or to make any
warranty or representation on behalf of the other party. Each party shall be
fully responsible for its own employees, servants and agents, and the employees,
servants and agents of one party shall not be deemed to be employees, servants
and agents of the other party for any purpose whatsoever.

         14.10 PUBLICITY. No press release or other public announcement shall be
made by either party concerning the execution of this Agreement or the fact that
Myogen has licensed the Compound from Abbott, without the prior written consent
of the non-disclosing party, which consent may be withheld in the non-disclosing
party's sole discretion. Neither party shall use the name of the other party,
its officers, employees or agents for purposes of any public commercial activity
without the other party's prior written consent, except where the name of the
other party must be disclosed as a matter of law. Should either party wish to
make a disclosure or be required by law to make a disclosure, the disclosing
party shall submit a copy of the proposed disclosure to the other party for
review. The non-disclosing party shall have three (3) weeks to review and
comment on the content of such disclosure. In the case of a disclosure required
by law, the disclosing party, subject to legal requirements, shall use all
reasonable efforts to

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

accommodate the non-disclosing party's comments. For non-routine matters like an
emergency, special circumstance, or other situation where the law compels a
disclosure in less than three (3) week's time, the non-disclosing party agrees
to use commercially reasonable efforts to provide its review and comment in
order to meet the disclosing party's timetable.

                  (REMAINDER OF PAGE INTENTIONALLY LEFT BLANK)

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the Effective Date.

ABBOTT DEUTSCHLAND                              MYOGEN, INC.
HOLDING GmbH

By:   /s/ Wolfgang Opperman                     By:   /s/ J. William Freytag
      ---------------------------                     --------------------------
Name: Wolfgang Opperman                         Name: J. William Freytag
      ---------------------------                     --------------------------
Its:  General Manager                           Its:  President
      ---------------------------                     --------------------------

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                    EXHIBIT A

                                       TO
                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ABBOTT LABORATORIES
                                       AND
                                  MYOGEN, INC.
                            DATED OCTOBER ____, 2001

                               PATENTS [...***...]

<Table>
<Caption>
   NO.        PRIORITY DATE           WO NUMBER          IN-HOUSE NO.              TITLE
   ---        -------------           ---------          ------------              -----
<S>           <C>                    <C>                <C>                     <C>
[...***...]
</Table>

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                    EXHIBIT B

                                       TO
                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ABBOTT LABORATORIES
                                       AND
                                  MYOGEN, INC.
                            DATED OCTOBER ____, 2001

                                    WORK PLAN

[...***...]

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                    EXHIBIT C

                                       TO
                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ABBOTT LABORATORIES
                                       AND
                                  MYOGEN, INC.
                             DATED __________, 2001

    FEASIBILITY AND EVALUATION STUDIES TO BE PERFORMED BY ABBOTT LABORATORIES

<Table>
<Caption>
    STUDY                      STATUS                       START DATE     TARGET COMPLETION   ESTIMATED COST*
    -----                      ------                       ----------     -----------------   ---------------
<S>                   <C>                               <C>               <C>                  <C>
[...***...]
</Table>

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                    EXHIBIT D

                                       TO
                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ABBOTT LABORATORIES
                                       AND
                                  MYOGEN, INC.
                            DATED OCTOBER ____, 2001

                         ALTERNATIVE DISPUTE RESOLUTION

         The parties recognize that from time to time a dispute may arise
relating to either party's right or obligations under this Agreement. The
parties agree that any such dispute shall be resolved by the Alternative Dispute
Resolution ("ADR") provisions set forth in this Exhibit, the result of which
shall be binding upon the parties.

         To begin the ADR process, a party first must send written notice of the
dispute to the other party for attempted resolution by good faith negotiations
between their respective presidents (or their designees) of the affected
subsidiaries, divisions, or business units within twenty-eight (28) days after
such notice is received (all references to "days" in this ADR provision are to
calendar days). If the matter has not been resolved within twenty-eight (28)
days of the notice of dispute, or if the parties fail to meet within such
twenty-eight (28) days, either party may initiate an ADR proceeding as provided
herein. The parties shall have the right to be represented by counsel in such a
proceeding.

1.       To begin an ADR proceeding, a party shall provide written notice to the
         other party of the issues to be resolved by ADR. Within fourteen (14)
         days after its receipt of such notice, the other party may, by written
         notice to the party initiating the ADR, add additional issues to be
         resolved within the same ADR.

2.       Within twenty-one (21) days following receipt of the original ADR
         notice, the parties shall select a mutually acceptable neutral to
         preside in the resolution of any disputes in this ADR proceeding. If
         the parties are unable to agree on a mutually acceptable neutral within
         such period, either party may request the President of the CPR
         Institute for Dispute Resolution ("CPR"), 366 Madison Avenue, 14th
         Floor, New York, New York 10017, to select a neutral pursuant to the
         following procedures:

         (a)      The CPR shall submit to the parties a list of not less than
                  five (5) candidates within fourteen (14) days after receipt of
                  the request, along with a Curriculum Vitae for each candidate.
                  No candidate shall be an

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  employee, director, or shareholder of either party or any of
                  their subsidiaries or affiliates.

         (b)      Such list shall include a statement of disclosure by each
                  candidate of any circumstances likely to affect his or her
                  impartiality.

         (c)      Each party shall number the candidates in order of preference
                  (with the number one (1) signifying the greatest preference)
                  and shall deliver the list to the CPR within seven (7) days
                  following receipt of the list of candidates. If a party
                  believes a conflict of interest exists regarding any of the
                  candidates, that party shall provide a written explanation of
                  the conflict to the CPR along with its list showing its order
                  of preference for the candidates. Any party failing to return
                  a list of preferences on time shall be deemed to have no order
                  of preference.

         (d)      If the parties collectively have identified fewer than three
                  (3) candidates deemed to have conflicts, the CPR immediately
                  shall designate as the neutral the candidate for whom the
                  parties collectively have indicated the greatest preference.
                  If a tie should result between two candidates, the CPR may
                  designate either candidate. If the parties collectively have
                  identified three (3) or more candidates deemed to have
                  conflicts, the CPR shall review the explanations regarding
                  conflicts and, in its sole discretion, may either (i)
                  immediately designate as the neutral the candidate for whom
                  the parties collectively have indicated the greatest
                  preference, or (ii) issue a new list of not less than five (5)
                  candidates, in which case the procedures set forth in
                  subparagraphs 2(a) - 2(d) shall be repeated.

3.       No earlier than twenty-eight (28) days or later than fifty-six (56)
         days after selection, the neutral shall hold a hearing to resolve each
         of the issues identified by the parties. The ADR proceeding shall take
         place at a location agreed upon by the parties. If the parties cannot
         agree, the neutral shall designate a location other than the principal
         place of business of either party or any of their subsidiaries or
         affiliates.

4.       At least seven (7) days prior to the hearing, each party shall submit
         the following to the other party and the neutral:

         (a)      a copy of all exhibits on which such party intends to rely in
                  any oral or written presentations to the neutral;

         (b)      a list of any witnesses such party intends to call at the
                  hearing, and a short summary of the anticipated testimony of
                  each witness;

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

         (c)      a proposed ruling on each issue to be resolved, together with
                  a request for a specific damage aware or other remedy for each
                  issue. The proposed rulings and remedies shall not contain any
                  recitation of the facts or any legal arguments and shall not
                  exceed one (1) page per issue.

         (d)      a brief in support of such party's proposed rulings and
                  remedies, provided that the brief shall not exceed twenty (20)
                  pages. This page limitation shall apply regardless of the
                  number of issues raised in the ADR proceeding.

         Except as expressly set forth in subparagraphs 4(a) - 4(d), no
         discovery shall be required or permitted by any means, including
         depositions, interrogatories, requests for admissions, or production of
         documents.

5.       The hearing shall be conducted on two (2) consecutive days and shall be
         governed by the following rules:

         (a)      Each party shall be entitled to five (5) hours of hearing time
                  to present its case. The neutral shall determine whether each
                  party has had the five (5) hours to which it is entitled.

         (b)      Each party shall be entitled, but not required, to make an
                  opening statement, to present regular and rebuttal testimony,
                  documents or other evidence, to cross-examine witnesses, and
                  to make a closing argument. Cross-examination of witnesses
                  shall occur immediately after their direct testimony, and
                  cross-examination time shall be charged against the party
                  conducting the cross-examination.

         (c)      The party initiating the ADR shall begin the hearing and, if
                  it chooses to make an opening statement, shall address not
                  only issues it raised but also any issues raised by the
                  responding party. The responding party, if it chooses to make
                  an opening statement, also shall address all issues raised in
                  the ADR. Thereafter, the presentation of regular and rebuttal
                  testimony and documents, other evidence, and closing arguments
                  shall proceed in the same sequence.

         (d)      Except when testifying, witnesses shall be excluded from the
                  hearing until closing arguments.

         (e)      Settlement negotiations, including any statements made
                  therein, shall not be admissible under any circumstances.
                  Affidavits prepared for purposes of the ADR hearing also shall
                  not be admissible. As to all other matters,

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                  the neutral shall have sole discretion regarding the
                  admissibility of any evidence.

6.       Within seven (7) days following completion of the hearing, each party
         may submit to the other party and the neutral a post-hearing brief in
         support of its proposed rulings and remedies, provided that such brief
         shall not contain or discuss any new evidence and shall not exceed ten
         (10) pages. This page limitation shall apply regardless of the number
         of issues raised in the ADR proceeding.

7.       The neutral shall rule on each disputed issue within fourteen (14) days
         following completion of the hearing. Such ruling shall adopt in its
         entirety the proposed ruling and remedy of one of the parties on each
         disputed issue but may adopt one party's proposed rulings and remedies
         on some issues and the other party's proposed rulings and remedies on
         other issues. The neutral shall not issue any written opinion or
         otherwise explain the basis of the ruling.

8.       The neutral shall be paid a reasonable fee plus expenses. These fees
         and expenses, along with the reasonable legal fees and expenses of the
         prevailing party (including all expert witness fees and expenses), the
         fees and expenses of a court reporter, and any expenses for a hearing
         room, shall be paid as follows:

         (a)      If the neutral rules in favor of one party on all disputed
                  issues in the ADR, the losing party shall pay 100% of such
                  fees and expenses.

         (b)      If the neutral rules in favor of one party on some issues and
                  the other party on other issues, the neutral shall issue with
                  the rulings a written determination as to how such fees and
                  expenses shall be allocated between the parties. The neutral
                  shall allocate fees and expenses in a way that bears a
                  reasonable relationship to the outcome of the ADR, with the
                  party prevailing on more issues, or on issues of greater value
                  or gravity, recovering a relatively larger share of its legal
                  fees and expenses.

9.       The rulings of the neutral and the allocation of fees and expenses
         shall be binding, non-reviewable, and non-appealable, and may be
         entered as a final judgment in any court having jurisdiction.

10.      Except as provided in paragraph 9 or as required by law, the existence
         of the dispute, any settlement negotiations, the ADR hearing, any
         submissions (including exhibits, testimony, proposed rulings, and
         briefs), and the rulings shall be deemed Confidential Information. The
         neutral shall have the authority to impose sanctions for unauthorized
         disclosure of Confidential Information.

                                                CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                     AND 230.406

                                    EXHIBIT E

                                       TO
                           EXCLUSIVE LICENSE AGREEMENT
                                     BETWEEN
                               ABBOTT LABORATORIES
                                       AND
                                  MYOGEN, INC.
                            DATED OCTOBER ____, 2001

 PRODUCT AND MATCHED PLACEBOS REQUIRED FOR AMBRISENTAN PHASE II CLINICAL TRIALS

                                   [...***...]

                                                CONFIDENTIAL TREATMENT REQUESTED<PAGE>
                                                                   EXHIBIT 10.19

                                [*#*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED
                                  IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
                                OMITTED AND FILED SEPARATELY WITH THE SECURITIES
                                    AND EXCHANGE COMMISSION PURSUANT TO RULE 406
                                      OF THE SECURITIES ACT OF 1933, AS AMENDED.

                        UNIVERSITY TECHNOLOGY CORPORATION
                     INTELLECTUAL PROPERTY LICENSE AGREEMENT

         This Agreement, effective the last date signatures are affixed hereto,
by and between the UNIVERSITY TECHNOLOGY CORPORATION a not-for-profit Colorado
corporation having its principal place of business at 3101 Iris Ave., Suite 250,
Boulder, Colorado 80301 U.S.A. (hereinafter referred to as UTC), and

                                  MYOGEN, INC.

a corporation duly organized under the laws of Delaware and having its principal
place of business at Fitzsimons Bldg. 500, P.O. Box 6366, Aurora, CO 80045-0366
(hereinafter referred to as LICENSEE).

                                    RECITALS

         WHEREAS, UTC is the owner of certain University of Colorado
intellectual property, embodied in inventions, patent rights, patents, patent
applications, copyrights or proprietary Know-How (as later defined herein and
referred to collectively as "Intellectual Property Rights"), related to [*#*]:

         CASE NO:              [*#*]
         PERTAINING TO:        [*#*]
         INVENTORS:            [*#*]

and has the right to grant licenses for aforementioned intellectual property,
subject only to a [*#*] United States Government, when applicable; and,

         WHEREAS, UTC desires to have the intellectual property utilized in the
public interest and is willing to grant a license such thereunder; and,

         WHEREAS, LICENSEE has represented to UTC in order to induce UTC to
enter into this Agreement, that LICENSEE shall commit itself to a diligent
program of exploiting such intellectual property commercially so that public
utilization and royalty income to UTC shall result therefrom; and,

         WHEREAS, LICENSEE desires to obtain a license under such intellectual
property upon the terms and conditions hereinafter set forth.

         NOW, THEREFORE, in consideration of the promises and the mutual
covenants contained herein the parties agree as follows:

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 2

                              ARTICLE 1 DEFINITIONS

         For the purposes of this Agreement, the following words and phrases
shall have the following meanings:

1.1 "LICENSEE" shall include Licensee; any related company of LICENSEE, the
voting stock of which is directly or indirectly at least fifty percent (50%)
owned or controlled by LICENSEE; an organization which directly or indirectly
controls at least fifty percent (50%) of the voting stock of LICENSEE; and, an
organization, at least fifty percent (50%) of which is directly or indirectly
common to the ownership of LICENSEE.

1.2 "Intellectual Property" shall mean all of the following UTC intellectual
property based on inventions and/or discoveries arising from research, work and
the like conducted by or under the direction or control of the University of
Colorado, including:

    (a) the invention disclosures, the United States and foreign patents, and/or
        patent applications and/or inventions listed in Appendix A;

    (b) the United States and foreign patents issued from applications covering
        the disclosures listed in Appendix A and from divisionals and
        continuations of these applications;

    (c) claims of U.S. and foreign continuation-in-part applications, and of the
        resulting patents, which claim priority to (a) and/or (b) above, and
        which are directed to subject matter specifically described in or
        dominated by the issued or pending claims of U.S. and foreign patent
        applications covering the disclosures listed in Appendix A;

    (d) claims of all foreign patent applications, and of the resulting patents,
        which claim priority to (a) and/or (b) above, and which are directed to
        subject matter described in the United States patents and/or patent
        applications described in (a), (b), or (c) above; and

    (e) any reissues of patents described in (a), (b), (c), or (d) above.

1.3 A "Licensed Product" shall mean any product or substantial part thereof
which:

    (a) is based on the Intellectual Property and/or which is covered in whole
        or in part by an issued, unexpired claim or a pending claim contained in
        the Intellectual Property and Know How in the country in which the
        Licensed Product is made, used or sold;

    (b) is manufactured using a Licensed Process;

    (c) is derived from Intellectual Property and/or Know-How.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 3

         1.4 A "Licensed Process" shall mean:

            (a)     any process which is covered in whole or in substantial part
                    by an issued, unexpired claim or a pending claim contained
                    in the Intellectual Property;

            (b)     is derived from Intellectual Property Rights and/or
                    Know-How.

         1.5 "Net Sales" of LICENSEE and/or its sublicensee shall [*#*].

In the event that the sale is made to an affiliate, the Net Sale will not be
less than an equivalent sale to a non-affiliate.

         1.6 "Know-How" shall mean any and all technical data, information, or
knowledge and, subject to Section 2.11 below, improvements, developments,
enhancements and the like which relate to the Licensed Product, the Licensed
Process or the manufacture, marketing, registration, purity, quality, potency,
safety, and efficacy of the Licensed Product or Licensed Process and which is
not in the public domain, and so long as maintained by the UTC as a trade
secret.

         1.7 "Territory" shall mean worldwide

         1.8 "Field of Use" shall mean human heart disease diagnosis, prevention
and therapy

         1.9 "Royalty Year" shall mean each consecutive twelve (12) month period
commencing with the Effective Date.

         1.10 "Derived From" shall mean products or processes created from
manipulating or modifying the Intellectual Property, and which would not be
possible but for the existence of the Intellectual Property.

                                 ARTICLE 2 GRANT

         2.1 UTC hereby grants to LICENSEE the exclusive right and license under
the Intellectual Property and Know How to make, have made, use, lease,
sublicense and sell the Licensed Products, and to practice the Licensed
Processes in the Territory for the Field of Use to the end of the term of the
last of the patents included in the Intellectual Property, to expire or
otherwise terminate, unless sooner terminated according to the terms hereof, and
Know-How for a term of twenty (20) years or until such time that the LICENSEE
can establish that such Know-How is available in the public domain.

         2.2 LICENSEE agrees that Licensed Products leased or sold in the United
States shall be manufactured substantially in the United States.

         2.3 UTC hereby agrees that it will not grant any other license to make,
have made, use, lease, sublicense and sell Licensed Products or to utilize
Licensed Processes in the Territory for the Field of Use during the period of
time commencing with the Effective Date of this Agreement and terminating with
the expiration of this Agreement.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 4

         2.4 UTC reserves the right to allow the University of Colorado and the
inventors to practice the Know-How and/or Intellectual Property for its or their
own research and educational purposes. It is understood that third parties are
not authorized to commercialize the Intellectual Property during the lifetime of
this Agreement.

         2.5 LICENSEE shall have the right to enter into sublicensing agreements
for the rights, privileges and licenses granted hereunder with UTC permission,
such consent not to be unreasonably withheld. LICENSEE shall provide written
notification to UTC of those license negotiations with potential sublicensees
that involve comprehensive and definitive terms.

         2.6 LICENSEE hereby agrees that every sublicensing agreement to which
it shall be a party and which shall relate to the rights, privileges and license
granted hereunder shall contain a statement setting forth the time at which
LICENSEE's exclusive rights, privileges and license hereunder shall terminate.

         2.7 LICENSEE agrees that any sublicenses granted by it shall provide
that the obligations to UTC of this Agreement shall be binding upon the
sublicensee as if it were a party to this Agreement.

         2.8 LICENSEE agrees to forward to UTC a copy of any and all sublicense
agreements within thirty (30) days of the execution of such sublicense
agreements and further agrees to forward to UTC annually a copy of reports
received by LICENSEE from its sublicensees during the preceding twelve (12)
month period under the sublicenses, as shall be pertinent to a royalty
accounting under said sublicense agreements.

         2.9 [*#*]

         2.10 The license granted hereunder shall not be construed to confer any
rights upon LICENSEE by assumption, implication, estoppel or otherwise as to any
technology not specifically set forth herein.

         2.11 LICENSEE shall own without restriction [*#*] all improvements to
the Intellectual Property and Know How, if applicable, or related products which
it develops. Improvements made jointly by LICENSEE and UTC, with substantial
contributions by both parties, shall be jointly and equally owned by LICENSEE
and UTC, without accounting.

                             ARTICLE 3 DUE DILIGENCE

         3.1 LICENSEE shall use commercially reasonable efforts to bring one or
more Licensed Products or Licensed Processes to market through a diligent
program for exploitation of the Know-How and/or Intellectual Property to
commercialize Licensed Products and/or Licensed Processes.

         3.2 In addition, LICENSEE, shall adhere to the following milestones:

            (a)     LICENSEE shall deliver to UTC on or before [*#*] a basic
                    business plan and forecast showing the funds, personnel, and
                    time budgeted and planned for development of the Licensed
                    Products and Licensed Processes and

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 5

                    shall provide similar reports or updates, as the case may
                    be, to UTC on an annual basis on or before the ninetieth
                    (90th) day following the close of LICENSEE's fiscal year.

            (b)     LICENSEE shall permit an in-plant inspection by UTC on or
                    before [*#*], and thereafter permit in-plant inspections
                    upon reasonable notice and reasonable times by UTC at
                    regular intervals with at least six (6) months between each
                    such inspection.

            (c)     LICENSEE together with its sublicensees shall have sold a
                    minimum of Licensed Products according to the following
                    schedule:

                    [*#*]

                    Minimum sales are subject to final negotiations and in-
                    licensing of Enoximone by Myogen from Hoechst Marion
                    Roussel.

         3.3 LICENSEE's failure to perform in accordance with Paragraphs 3.1 and
3.2 above or to pay amounts in lieu thereof shall be grounds for UTC to reduce
the exclusive license under this Agreement to a nonexclusive one, provided that
at least [*#*] of the Net Sales are achieved, and failing that terminate this
Agreement pursuant to Paragraph 13.3 hereof unless both parties renegotiate the
Due Diligence plan and mutually agree to revisions thereto.

              ARTICLE 4 MONETARY CONSIDERATION, INCLUDING ROYALTIES

         4.1 For the rights, privileges and license granted hereunder, LICENSEE
shall make payments to UTC in the manner hereinafter provided [*#*] or until
this Agreement shall be terminated as hereinafter provided:

            (a)     LICENSE ISSUE FEE of [*#*] which shall be deemed earned
                    and due immediately upon the execution of this Agreement.

            (b)     LICENSE MAINTENANCE FEES of [*#*] per year payable on
                    January 1, 1999 and on January 1 of each year thereafter for
                    the term of this Agreement.

            (c)     RUNNING ROYALTIES AS FOLLOWS:

                    (i)     [*#*] of Net Sales [*#*] of the Licensed
                            Products by LICENSEE, [*#*]

                   (ii)     the lesser of (A) [*#*] of Net Sales by
                            sublicensees of the Licensed Products or (B) [*#*]
                            of the amount of royalty payments received by
                            LICENSEE from such Net Sales by sublicensees,
                            provided that in no event will this amount exceed
                            [*#*] of sublicensees' Net Sales.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 6

         In the event of extenuating circumstances, royalty rates for any given
technology will be renegotiated in good faith.

            (d)     In addition to the foregoing, LICENSEE agrees that it will
                    remit to UTC [*#*] which it may receive from any
                    sublicensee in relation to Licensed Products and/or Licensed
                    Processes and/or Know-How.

            (e)     [*#*]

         4.2 No multiple royalties shall be payable because any Licensed
Product, its manufacture, use, lease or sale are or shall be covered by more
than one Intellectual Property patent application or Intellectual Property
patent licensed under this Agreement.

         4.3 LICENSEE shall be entitled to reduce the royalty rates set forth
above in the event that it becomes necessary for the LICENSEE to license
intellectual property rights owned by third parties to develop, discover,
identify, use, make or sell Licensed Products. Such reduction shall be equal to
[*#*] the sum of earned royalties paid to such third parties. However, in no
case shall the royalty paid to UTC be less than [*#*] of the amounts otherwise
due for Licensed Products.

         4.4 If any Licensed Product is sold in combination with other products
which are not within the scope of the Intellectual Property, the royalties due
to UTC will be based on [*#*]

         4.5 If this Agreement is not terminated in accordance with other
provision hereof, LICENSEE's obligation to pay earned royalties hereunder shall
continue until [*#*], on a country by country basis, covering said activity.
Thereafter, LICENSEE shall have no obligation with respect to royalties, unless
and to the extent any substantial Know How remains, in which case all royalty
amounts shall be reduced by [*#*] for a period of [*#*], or such earlier
time if such Know How enters the public domain or becomes substantially of no
value, after which time all royalty obligations shall cease entirely.

         4.6 Royalty payments shall be paid in United States dollars in Boulder,
Colorado or at such other place as UTC may reasonably designate consistent with
the laws and regulations controlling in any foreign country. If any currency
conversion shall be required in connection with the payment of royalties
hereunder, such conversion shall be made by [*#*].

                                ARTICLE 5 OPTIONS

         Minimum Research Support payments, at LICENSEE's discretion of [***]
per year, in order to secure, under terms and conditions similar to those of
this Agreement, a first option on new inventions in the Field of Use (in the
absence of any third-party obligations to the contrary) arising from a specific
laboratory, which includes the UCHSC heart tissue bank (the "Tissue Bank")
directed by a University of Colorado faculty member. It is understood that
LICENSEE commits to at least one year of research support at the Tissue Bank
pursuant to the Materials Transfer Agreement between LICENSEE and UCHSC, and
that the $59,000 reimbursement under that agreement satisfies the first year of
research support under this section Article V of this Agreement. Royalty rates
for such licensed acquisitions will be

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 7

identical to those listed herein, plus a one-time Technology Acquisition Fee of
five thousand dollars ($5,000).

                          ARTICLE 6 REPORTS AND RECORDS

         6.1 LICENSEE shall keep full, true and accurate books of account
containing all particulars that may be necessary for the purpose of showing the
amounts payable to UTC hereunder. Said books of account shall be kept at
LICENSEE's principal place of business or the principal place of business of the
appropriate division of LICENSEE to which this Agreement relates. Said books and
the supporting data shall be open at all reasonable times for three (3) years
following the end of the calendar year to which they pertain, to the inspection
of UTC or its agents for the purpose of verifying LICENSEE's royalty statement
or compliance in other respects with this Agreement.

         6.2 LICENSEE, within forty-five (45) days after March 31, June 30,
September 30 and December 31, of each year, shall deliver to UTC true and
accurate reports, giving such particulars of the business conducted by LICENSEE
during the preceding three-month period under the Agreement as shall be
pertinent to a royalty accounting hereunder. These shall include at least the
following:

             [*#*]

         6.3 With each such report submitted, LICENSEE shall pay to UTC the
royalties due and payable under this Agreement. If no royalties shall be due,
LICENSEE shall so report.

         6.4 During the period this Agreement is in effect, on or before the
ninetieth (90th) day following the close of LICENSEE's fiscal year, LICENSEE
shall provide UTC with LICENSEE's certified financial statements for the
preceding fiscal year including, at a minimum, a Balance Sheet and an Operating
Statement.

         6.5 The royalty payments set forth in this Agreement shall, if overdue,
bear interest until payment at the monthly rate of [*#*]. The payment of such
interest shall not foreclose UTC from exercising any other rights it may have as
a consequence of the lateness of any payment.

                          ARTICLE 7 PATENT PROSECUTION

         7.1 LICENSEE, in its sole discretion, shall apply for, seek issuance
of, and maintain during the term of this Agreement the Intellectual Property
Rights in [*#*]. The prosecution, filing and maintenance of all Intellectual
Property patents and applications shall be the primary responsibility of
LICENSEE. However, UTC shall have reasonable opportunities to advise LICENSEE
and shall cooperate with LICENSEE in such prosecution, filing and maintenance.
In the event LICENSEE abandons efforts in this regard, UTC may assume such
responsibilities at its own expense.

         7.2 Payment of all fees & costs relating to the filing, prosecution,
& maintenance of the Intellectual Property shall be the responsibility of
Licensee, as long as the license under this Agreement remains exclusive.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 8

                             ARTICLE 8 INFRINGEMENT

         8.1 Either party shall inform the other promptly in writing of any
alleged infringement of the Intellectual Property Rights by a third party and of
any available evidence thereof.

         8.2 During the term of this Agreement, UTC shall have the right, but
shall not be obligated, to prosecute at its own expense any such infringements
of the Intellectual Property Rights. If UTC prosecutes any such infringement,
UTC agrees that LICENSEE may join UTC as a party plaintiff in any such suit,
without expense to LICENSEE. The total cost of any such infringement action
commenced or defended solely by UTC shall be borne by UTC and UTC shall keep any
recovery or damages for past infringement derived therefrom.

         8.3 If within six (6) months after having been notified of any alleged
infringement or such shorter time prescribed by law, UTC shall have been
unsuccessful in persuading the alleged infringer to desist and shall not have
brought and shall not be diligently prosecuting an infringement action, or if
UTC shall notify LICENSEE at any time prior thereto of its intention not to
bring suit against any alleged infringer, then, and in those events only,
LICENSEE shall have the right, but shall not be obligated, to prosecute [*#*]
any infringement of the Intellectual Property, and LICENSEE may, for such
purposes, use the name of UTC as party plaintiff; provided, however, that such
right to bring an infringement action shall remain in effect only for so long as
the license granted herein remains exclusive. No settlement, consent judgment or
other voluntary final disposition of the suit may be entered into without the
consent of UTC, which consent shall not unreasonably be withheld. [*#*]
LICENSEE shall keep any recovery or damages for past infringement derived
therefrom when the cost of such action is borne solely by LICENSEE.

         8.4 In the event that LICENSEE and UTC jointly shall undertake the
enforcement and/or defense of the Intellectual Property by litigation, then all
costs and judgments shall [*#*].

         8.5 In the event that a declaratory judgment action alleging invalidity
or noninfringement of any of the Intellectual Property shall be brought against
LICENSEE, UTC at its option, shall have the right, within thirty (30) days after
commencement of such action, to intervene and take over the sole defense of the
action at its own expense.

         8.6 In any infringement suit as either party may institute to enforce
the Intellectual Property Rights pursuant to this Agreement, the other party
hereto shall, at the request and expense of the party initiating such suit,
cooperate in all respects and, to the extent possible, have its employees
testify when requested and make available relevant records, papers, information,
samples, specimens, and the like.

         8.7 In the event of any infringement or likely infringement by
LICENSEE's use, manufacture or sale of any of the Intellectual Property, Know
How, Licensed Product, or Licensed Process of any third party's intellectual
property (collectively, "Infringing Rights"), UTC shall, together with LICENSEE,
cooperate in good faith and on a mutual and reasonable basis, with each party
responsible for its respective expenses:

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 9

            (a)     To negotiate and settle any dispute with any such third
                    party concerning the Infringing Rights, and otherwise
                    resolve any such infringement and secure LICENSEE's
                    continued rights to the Infringing Rights; and

            (b)     To make a reasonable and equitable adjustment, if any, to
                    the royalties paid or otherwise due under this Agreement in
                    respect of licenses or other rights obtained by LICENSEE
                    from third parties under such Infringing Rights in order for
                    LICENSEE to continue to exercise rights granted under this
                    Agreement.

         8.8 In no event shall any party to this Agreement be liable for
indirect, consequential or similar damages, even if advised of the possibility
of such liability.

                           ARTICLE 9 PRODUCT LIABILITY

         9.1 LICENSEE shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold UTC, its trustees, board members,
officers, employees and affiliates, as well as those of the University of
Colorado harmless against all claims and expenses, including legal expenses and
reasonable attorney's fees, arising out of the death of or injury to any person
or persons or out of any damage to property and against any other claim,
proceeding, demand, expense and liability of any kind whatsoever resulting from
the production, manufacture, sale, use, lease, consumption or advertisement of
the Licensed Products and/or Licensed Processes by LICENSEE pursuant to this
Agreement.

         9.2 LICENSEE shall obtain and carry in full force and effect liability
insurance which shall protect LICENSEE and UTC in regard to events covered by
Paragraph 9.1 above.

         9.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, UTC
MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIM[ITED TO WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, AND VALIDITY OF INTELLECTUAL PROPERTY RIGHTS CLAIMS,
ISSUED OR PENDING.

                           ARTICLE 10 EXPORT CONTROLS

         It is understood that UTC is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on compliance with applicable United States
export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by LICENSEE that LICENSEE shall not export
data or commodities to certain foreign countries without prior approval of such
agency. UTC neither represents that a license shall not be required nor that, if
required, it shall be issued.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 10

                           ARTICLE 11 NON-USE OF NAMES

         LICENSEE shall not use the names of UTC and/or the University of
Colorado nor any of their employee's, nor any adaptation thereof, in any press
release, advertising, promotional or sales literature without prior written
consent obtained from UTC in each case, not to be unreasonably withheld or
delayed, except that LICENSEE may state that it is licensed by UTC and the
University of Colorado under one or more of the patents and/or applications
comprising the Intellectual Property Rights. UTC has the right to state the
existence of this license, the subject matter, and the LICENSEE, though any
terms and details cannot be a released to the public without the written consent
of LICENSEE.

                              ARTICLE 12 ASSIGNMENT

         This Agreement is not assignable and any attempt to do so shall be
void; provided, however, that either party may assign this Agreement to any
party acquiring all or substantially all of the assets and business of such
party.

                             ARTICLE 13 TERMINATION

         13.1 If LICENSEE shall cease to carry on its business or initiate or
conduct actions in order to declare a state of bankruptcy, this Agreement shall
terminate upon notice by UTC.

         13.2 Should LICENSEE fail to pay UTC royalties due and payable
hereunder, UTC shall have the right to terminate this Agreement on thirty (30)
days' notice, unless LICENSEE shall pay UTC within the thirty (30) day period,
all such royalties and interest due and payable. Upon the expiration of the
thirty (30) days period, if LICENSEE shall not have paid all such royalties and
interest due and payable, the rights, privileges and license granted hereunder
shall terminate.

         13.3 Upon any material breach or default of this Agreement by LICENSEE,
other than those occurrences set out in Paragraphs 13.1 and 13.2 hereinabove,
which shall always take precedence in that order over any material breach or
default referred to in this Paragraph 13.3, UTC shall have the right to
terminate this Agreement and the rights, privileges and license granted
hereunder by ninety (90) days' notice to LICENSEE. Such termination shall become
effective unless LICENSEE shall have cured any such breach or default prior to
the expiration of the ninety (90) day period.

         13.4 LICENSEE shall have the right to terminate this Agreement at any
time on six (6) months' notice to UTC, [*#*].

         13.5 UTC may terminate this Agreement upon the occurrence of the third
separate instance of LICENSEE's failure to pay royalties when due within any
consecutive three (3) year period.

         13.6 Upon termination of this Agreement for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination. LICENSEE and any sublicensee
thereof may, however, after the effective date

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 11

of such termination, sell all Licensed Products, and complete Licensed Products
in the process of manufacture at the time of such termination and sell the same,
provided that LICENSEE shall pay to UTC the royalties thereon as required by
Article IV of this Agreement and shall submit the reports required by Article VI
hereof on the sales of Licensed Products.

         13.7 Upon termination of this Agreement for any reason, any sublicensee
not then in default shall have the right to seek a license from UTC.

              ARTICLE 14 PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

         Any payment, notice or other communication pursuant to this Agreement
shall be sufficiently made or given on the date of mailing if sent to such party
by certified first class mail, postage prepaid, addressed to it at its address
below or as it shall designate by written notice given to the other party:

         In the case UTC:         UNIVERSITY TECHNOLOGY CORPORATION:
                                  3101 Iris Ave., Suite 250
                                  Boulder, Colorado 80301
                                  Attn:  Michael G. Gabridge, Ph.D., President
                                           and CEO

         In the case of LICENSEE: MYOGEN, INC.:
                                  Fitzsimons Bldg. 500, P.O. Box 6366
                                  Aurora, CO 80045-0366
                                  Attn: J. William Freytag, President

           ARTICLE 15 PUBLICATIONS ARISING FROM LICENSEE R & D SUPPORT

         15.1 LICENSEE recognizes that UTC's relationship with the University of
Colorado requires that the results of University of Colorado's research must be
publishable and agrees that University of Colorado personnel engaged in research
pertinent to Know-How and/or Intellectual Property shall be permitted to present
at symposia, national or regional professional meetings and to publish in
journals, theses or dissertations, or otherwise of their own choosing, methods
and results of research, provided, however, that LICENSEE shall have been
furnished copies of any proposed publication or presentation at least forty-five
(45) days in advance of the submission of such proposed publication or
presentation to a journal, editor or other third party when LICENSEE has
provided the majority of the research funding which lead to the results
presented in manuscript form.

         15.2 LICENSEE shall have thirty (30) days, after receipt of said
copies, to object to such proposed presentation or proposed publication pursuant
to Article 15.1 above, either because there is patentable subject matter which
needs protection and/or there is confidential information of LICENSEE contained
in the proposed publication or presentation. In the event that LICENSEE makes
such objection, the University of Colorado personnel shall refrain from making
such publication or presentation for a maximum of three (3) months in order for
the LICENSEE to file patent applications with the United States Patent and
Trademark Office and/or foreign patent office(s) directed to the Patentable
subject matter contained in the proposed publication or presentation.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 12

                            ARTICLE 16 MISCELLANEOUS

         16.1 This Agreement shall be construed, governed, interpreted and
applied in accordance with the laws of the State of Colorado, USA, except that
questions affecting the construction and effect of any patent shall be
determined by the law of the country in which the patent was granted.

         16.2 The parties hereto acknowledge that this Agreement sets forth the
entire Agreement and understanding of the parties hereto as to the subject
matter hereof, and shall not be subject to any change or modification except by
the execution of a written instrument subscribed to by the parties hereto.

         16.3 The provisions of this Agreement are severable, and in the event
that any provisions of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

         16.4 LICENSEE agrees to mark or otherwise identify the Licensed
Products sold in the United States with all applicable United States patent
numbers. All Licensed Products shipped to or sold in other countries shall be
marked in such a manner as to conform with the patent laws and practice of the
country of manufacture or sale.

         16.5 The failure of either party to assert a right hereunder or to
insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other party.

         16.6 This Agreement may be executed in counterpart, and may be executed
and delivered by facsimile.

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 13

         IN WITNESS WHEREOF, the parties have hereunto set their hands and seals
and duly executed this Agreement the day and year set forth below, effective the
later of the dates below.

UNIVERSITY TECHNOLOGY CORPORATION

By:               /s/ Michael G. Gabridge
         --------------------------------------------
         Michael G. Gabridge, Ph.D.
         President and CEO

Date:             Sept 1, 1998
         --------------------------------------------

MYOGEN, INC.

By:               /s/ J. William Freytag
         --------------------------------------------
         J. William Freytag
         President

Date:             01-Sep '98
         --------------------------------------------

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>
License Agreement
Page 14

                                   APPENDIX A

[*#*]

                                             *#*CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                        UNIVERSITY TECHNOLOGY CORPORATION

                                  AMENDMENT TO
                     INTELLECTUAL PROPERTY LICENSE AGREEMENT

         THIS AMENDMENT dated effective as of January 26, 2001 ("Effective
Date"), is to that certain Intellectual Property License Agreement ("License
Agreement") executed September 1, 1998, between UNIVERSITY TECHNOLOGY
CORPORATION, a Colorado nonprofit corporation ("UTC") and MYOGEN, INC.
("Myogen"), a Delaware corporation, having its principal place of business at
7577 W. 103rd Avenue, Westminster, Colorado. Unless otherwise provided, the
capitalized terms used herein have the same meaning as attributed to them in the
License Agreement.

         WHEREAS, under the License Agreement, UTC licensed certain Intellectual
Property on an exclusive basis to Myogen, and

         WHEREAS, [*#*] is an employee of the University of Colorado ("CU") and
one of the inventors of the Intellectual Property relating to [*#*] (the
"Subject Technology"), and

         WHEREAS, [*#*] desires to conduct research using the Subject Technology
under a sponsored research agreement entitled, [*#*] (the "Sponsored Research
Agreement") sponsored by a third-party corporate entity (the "Sponsor"), and

         WHEREAS, Myogen believes that research under the Sponsored Research
Agreement has the potential to further validate the utility of the Subject
Technology,

         NOW THEREFORE, in consideration of the mutual covenants and agreements
by the parties, the parties agree as follows:

         1. Amendment to License Agreement. The parties agree that as of the
Effective Date, the Subject Technology may be used by [*#*] in his work under
the Sponsored Research Agreement.

         2. Commercialization. The parties agree that notwithstanding Section
2.4 of the License Agreement, the Sponsor may exploit and commercialize the data
or results of the Sponsored Research Agreement in the laboratories of [*#*] as
it may determine in its sole discretion [*#*].

         3. No Other Amendment. Except as amended herein, the terms of the
License Agreement remain in full force and effect.

                                       1.

                                            *** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

         IN WITNESS WHEREOF, the parties have duly executed this Amendment as of
the Effective Date.

UNIVERSITY TECHNOLOGY                  MYOGEN, INC
CORPORATION

By:  /s/ Jerry Donahue                 By:  /s/ J. William Freytag
   --------------------------------       --------------------------------------
     Jerry Donahue, President               J. William Freytag, Ph.D., President

                                       2.

                                          [*#*] CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]